Combining 1,4-dimethoxybenzene, the major flower volatile of wild strawberry Fragaria vesca, with the aggregation pheromone of the strawberry blossom weevil Anthonomus rubi improves attraction

The aggregation pheromone of strawberry blossom weevil [Anthonomus rubi Herbst (Col.: Curculionidae)], a 1:4:1 blend of Grandlure I, II and racemic lavadulol, has been available for pest monitoring for several years but shows low attractancy. Attempts to control A. rubi using the pheromone alone were also unsuccessful. This paper reports the finding that addition of the major flower volatile from wild strawberry flowers [Fragaria vesca L. (Rosaceae)], 1,4-dimethoxybenzene (comprising 98% of the volatiles emitted from wild strawberry flowers), to the aggregation pheromone increased trap catches by over two fold compared to the pheromone alone. There was no significant difference between the response of overwintered or summer emerged adults. Field trials in 2007-2008 in central and southern Norway, Denmark and southern England used green funnel traps with white cross vanes for the evaluations. (-)-Germacrene D, previously shown to be emitted by plants in increased amounts in the presence of pheromone producing weevils, did not improve trap catches. Thus, the combined use of the aggregation pheromone and 1,4-dimethoxybenzene is promising for improved monitoring and possibly control of this important pest of strawberry

New depth record of the precious red coral Corallium rubrum for the Mediterranean

Live colonies of the precious red coral Corallium rubrum have previously been recorded at depths of 600 -800 m in the Sicily Channel, but deep -water populations of this species remain poorly known. During a recent research expedition within the 25 nautical mile Fisheries Management Zone around the Maltese Islands, numerous colonies growing deeper than 800 m, down to depths of 1016 m were observed. These colonies were part of a diverse community of habitat -forming species of scleractinians, gorgonians and antipatharians.peer-reviewe

On the occurrence of Coronaster briareus (Echinodermata, Forcipulatida, Asteriidae) in the Mediterranean Sea

The sea star Coronaster briareus (Verrill Am J Sci (Ser III), 1882) is reported for the first time from the Mediterranean Sea. A total of 26 individuals were sighted in Maltese waters during ROV surveys made in July 2015 and June–July 2016. The identity of the species was confirmed through morphological examination of a specimen collected in June 2016. This identification is discussed in the light of inconsistencies in the published descriptions of species of Coronaster recorded from the Atlantic, and of individuals belonging to this genus recorded from the eastern Atlantic and whose coloration does not match that of C. briareus or C. volsellatus (the only species of Coronaster hitherto known from the Atlantic). The presence of numerous individuals of C. briareus in Maltese waters, recorded on two occasions a year apart over a relatively large area, indicates that there is an established population. This represents a considerable expansion of the distribution range of this species, which is mostly known from the western Atlantic. Possible reasons for its presence in Maltese waters are discussed, but the dynamics of the occurrence of C. briareus in the central Mediterranean remain unknown.peer-reviewe

Recent evidence that the deep sea around Malta is a biodiversity hotspot

Recent ROV surveys of deep-sea areas around the Maltese Islands resulted in the discovery of highly diverse habitats, including extensive rocky areas dominated by living cold water corals and gorgonians at depths of 300–1000 m, a sub-fossil lithistid sponge reef at a depth of ca. 300 m, deep-water caves located at 270–450 m, and vast expanses of soft-bottom habitats, each of which had a rich variety of associated fauna. Most of these habitats are of high conservation interest, highlighting the need for the establishment of offshore marine protected areas in order to protect these very diverse, but highly vulnerable, deep-sea habitats.peer-reviewe

<i>HER2</i>-encoded mir-4728 forms a receptor-independent circuit with miR-21-5p through the non-canonical poly(A) polymerase PAPD5

We previously reported that the human HER2 gene encodes the intronic microRNA mir-4728, which is overexpressed together with its oncogenic host gene and may act independently of the HER2 receptor. More recently, we also reported that the oncogenic miR-21-5p is regulated by 3′ tailing and trimming by the non-canonical poly(A) polymerase PAPD5 and the ribonuclease PARN. Here we demonstrate a dual function for the HER2 locus in upregulation of miR-21-5p; while HER2 signalling activates transcription of mir-21, miR-4728-3p specifically stabilises miR-21-5p through inhibition of PAPD5. Our results establish a new and unexpected oncogenic role for the HER2 locus that is not currently being targeted by any anti-HER2 therapy

Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer.

Large cell carcinoma with or without neuroendocrine features (LCNEC and LC, respectively) constitutes 3-9% of non-small cell lung cancer but is poorly characterized at the molecular level. Herein we analyzed 41 LC and 32 LCNEC (including 15 previously reported cases) tumors using massive parallel sequencing for mutations in 26 cancer-related genes and gene fusions in ALK, RET, and ROS1. LC patients were additionally subdivided into three immunohistochemistry groups based on positive expression of TTF-1/Napsin A (adenocarcinoma-like, n = 24; 59%), CK5/P40 (squamous-like, n = 5; 12%), or no marker expression (marker-negative, n = 12; 29%). Most common alterations were TP53 (83%), KRAS (22%), MET (12%) mutations in LCs, and TP53 (88%), STK11 (16%), and PTEN (13%) mutations in LCNECs. In general, LCs showed more oncogene mutations compared to LCNECs. Immunomarker stratification of LC revealed oncogene mutations in 63% of adenocarcinoma-like cases, but only in 17% of marker-negative cases. Moreover, marker-negative LCs were associated with inferior overall survival compared with adenocarcinoma-like tumors (p = 0.007). No ALK, RET or ROS1 fusions were detected in LCs or LCNECs. Together, our molecular analyses support that LC and LCNEC tumors follow different tumorigenic paths and that LC may be stratified into molecular subgroups with potential implications for diagnosis, prognostics, and therapy decisions

Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis

Background: Infections due to antibiotic-resistant bacteria are threatening modern health care. However, estimating their incidence, complications, and attributable mortality is challenging. We aimed to estimate the burden of infections caused by antibiotic-resistant bacteria of public health concern in countries of the EU and European Economic Area (EEA) in 2015, measured in number of cases, attributable deaths, and disability-adjusted life-years (DALYs). Methods: We estimated the incidence of infections with 16 antibiotic resistance–bacterium combinations from European Antimicrobial Resistance Surveillance Network (EARS-Net) 2015 data that was country-corrected for population coverage. We multiplied the number of bloodstream infections (BSIs) by a conversion factor derived from the European Centre for Disease Prevention and Control point prevalence survey of health-care-associated infections in European acute care hospitals in 2011–12 to estimate the number of non-BSIs. We developed disease outcome models for five types of infection on the basis of systematic reviews of the literature. Findings: From EARS-Net data collected between Jan 1, 2015, and Dec 31, 2015, we estimated 671 689 (95% uncertainty interval [UI] 583 148–763 966) infections with antibiotic-resistant bacteria, of which 63·5% (426 277 of 671 689) were associated with health care. These infections accounted for an estimated 33 110 (28 480–38 430) attributable deaths and 874 541 (768 837–989 068) DALYs. The burden for the EU and EEA was highest in infants (aged <1 year) and people aged 65 years or older, had increased since 2007, and was highest in Italy and Greece. Interpretation: Our results present the health burden of five types of infection with antibiotic-resistant bacteria expressed, for the first time, in DALYs. The estimated burden of infections with antibiotic-resistant bacteria in the EU and EEA is substantial compared with that of other infectious diseases, and has increased since 2007. Our burden estimates provide useful information for public health decision-makers prioritising interventions for infectious diseases

Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA

AimThe aim of the present study was to assess beta cell function based on an oral glucose tolerance test (OGTT) in participants with single islet autoantibody or an intravenous glucose tolerance test (IvGTT) in participants with multiple islet autoantibodies.Materials and methodsHealthy participants in Sweden and Finland, between 2 and 49.99 years of age previously identified as positive for a single (n = 30) autoantibody to either insulin, glutamic acid decarboxylase, islet antigen-2, zinc transporter 8 or islet cell antibodies or multiple autoantibodies (n = 46), were included. Participants positive for a single autoantibody underwent a 6-point OGTT while participants positive for multiple autoantibodies underwent an IvGTT. Glucose, insulin and C-peptide were measured from OGTT and IvGTT samples.ResultsAll participants positive for a single autoantibody had a normal glucose tolerance test with 120 minutes glucose below 7.70 mmol/L and HbA1c values within the normal range (ConclusionParticipants positive for a single autoantibody appeared to have a normal beta cell function. Participants positive for three or more autoantibodies had a lower FPIR as compared to participants with two autoantibodies, supporting the view that their beta cell function had deteriorated.</p

Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates. Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS. Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2 x 10(53)). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2 x 10(-20)). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS. Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management